Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-22 18:52 CEST (UTC+2h)

syrup hybrid application [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-09-07 14:10  - Posting: # 17792
Views: 1,924

Dear Aga,

» If we would go 10.3 - how we should prove equivalence with this tricky syrup? Bioequivalence - because the product is not pharmaceutically equivalent? or can we somehow prove pharmaceutical equivalence with double dose vs single dose? Is it possible?

I really meant what I said - this can be perceived completely heterogeneously between countries. You may get as many answers as there are agencies. Therefore, take scientific advices (pl.) and try to rely on that. They may need in vivo studies, or they may not. They may need ther. equivalence in stead of bioequivalence, or they may not. They may let you get away with some in vitro work, or they may not. They may accept a bunch of literature, or they may not. They may be totally paranoid and conservative because you are doing something related to children, or they may not.
Request scientific advice. Even if there is no budget and no time.:-)

Note also that BE does not have the same definition in EU and US.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,418 posts in 3,912 threads, 1,173 registered users;
online 19 (1 registered, 18 guests [including 10 identified bots]).

The greatest shortcoming of the human race is our inability
to understand the exponential function.    Albert Bartlett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed